COVAX No-Fault Compensation Program for AMC Eligible Economies


The purpose of the Program is to provide no-fault lump-sum compensation in full and final settlement of any claims to eligible individuals who suffer a serious adverse event resulting in permanent impairment or death associated with a COVID-19 vaccine procured or distributed through the COVAX Facility in any Gavi AMC eligible economy until 30 June 2022, or the administration of such a vaccine. Gavi AMC eligible economies are the 92 low- and middle-income countries and economies eligible for support via the Gavi COVAX Advance Market Commitment (AMC) of the COVAX Facility. The Program is subject to the terms of its Protocol and applicable Program forms (see below).